Sanofi And Genzyme Move Closer To A Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies enter confidentiality agreement allowing Sanofi to conduct due diligence and reportedly have agreed on outlines of a deal.
You may also be interested in...
Genzyme, Sanofi Mum On Merger Negotiations At JPM Conference
Genzyme depicts itself as the picture of health with enzyme replacement therapy business returning to normal after manufacturing woes.
Sanofi Extends $69-Per-Share Tender Offer For Genzyme To Jan. 21
Less than 1% of outstanding shares had been tendered as of Dec. 10 deadline.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.